Abstract
The drug rapamycin has beneficial effects in a number of animal models of neurodegeneration and aging including mouse models of Alzheimer's disease. Despite its compelling preclinical record, no clinical trials have tested rapamycin or other mTOR inhibitors in patients with Alzheimer's disease. We argue that such clinical trials should be undertaken.
Original language | English (US) |
---|---|
Article number | eaar4289 |
Journal | Science translational medicine |
Volume | 11 |
Issue number | 476 |
DOIs | |
State | Published - Jan 23 2019 |
ASJC Scopus subject areas
- Medicine(all)